FundaMental Pharma launches with EUR 10 million in Seed financing to advance a First-in-Class neuroprotectant
"These inhibitors have the potential to revolutionize therapies for currently untreatable neurodegenerative diseases"
21-Nov-2022 -
FundaMental Pharma GmbH, a preclinical neuroscience company spun out of Heidelberg University, announces that it has launched with EUR 10 million in seed financing led by BioGeneration Ventures (BGV) and Thuja Capital, with participation from other investors, including coparion and High-Tech ...
amyotrophic lateral sclerosis
glutamate
Huntington's disease
+6